DNK is a technology company.
DNK has raised $20.0M across 2 funding rounds.
DNK has raised $20.0M in total across 2 funding rounds.
DNK has raised $20.0M in total across 2 funding rounds.
DNK's investors include Andreessen Horowitz, Dream Machine, Electric Ant, Flybridge Capital Partners, Greylock, Balaji Srinivasan, 75 & Sunny, David Vélez, Hadi Partovi, Kaszek Ventures, Latitud, NFX.
DNK Technology LLC (DNA-Technology Group) is a technology company specializing in molecular diagnostics, developing and producing high-tech equipment and reagents for PCR (polymerase chain reaction) analysis since 1993.[1][4] It serves hospitals and laboratories worldwide through a distribution network in over 40 countries, offering a wide portfolio of PCR kits and equipment to apply molecular biology advances to routine diagnostics, improving treatment outcomes and clinical prognosis.[1] The company maintains high standards with ISO 13485:2016 and ISO 9001:2015 certifications, plus CE IVD compliance for its medical devices.[1]
Note: Multiple entities share similar names, including DKN-Technology (fitness equipment since 1991)[2], D&K Technologies (now Upstair Technologies, IT services in India)[3], and DNK (property management software for APAC rentals).[5] This overview focuses on DNK Technology LLC as the clearest match for a longstanding tech firm in biotech, based on query phrasing and search prominence.[1][4]
Founded in 1993, the DNA-Technology Group (operating as DNK Technology LLC) emerged from a team of experts in molecular biology, immunogenetics, medicine, thermodynamics, optics, electronics, and programming.[1][4] This multidisciplinary expertise drove its initial focus on developing PCR-based solutions, preserving high research potential and quality control from the start.[1] Early milestones include building a global distribution network supplying products to over 40 countries, with consistent innovation in PCR kits and equipment for lab integration.[1] Pivotal growth came from certifications like ISO 13485:2016 and CE IVD, enabling regulatory compliance and market expansion for IVD medical devices.[1]
DNK Technology rides the wave of precision medicine and molecular diagnostics, where PCR remains essential for rapid pathogen detection, genetic testing, and personalized treatments amid rising global health demands.[1] Timing aligns with post-pandemic emphasis on scalable biotech tools, as labs seek reliable, certified equipment to handle infectious diseases and genomics.[1][4] Market forces like regulatory harmonization (e.g., EU IVD directives) and expanding lab networks in emerging regions favor its global distribution model.[1] It influences the ecosystem by bridging research and routine practice, enabling better diagnostics in underserved areas and supporting broader adoption of molecular methods in healthcare.[1]
DNK Technology is poised to expand in growing diagnostics markets, leveraging its 30+ years of PCR expertise amid trends like AI-enhanced genomics and point-of-care testing. Expect deeper integration with digital lab workflows and potential partnerships for multiplex assays, amplifying its role in global health resilience. As biotech democratizes advanced tools, DNK's certified, accessible solutions will likely solidify its niche, much like its foundational push from research to worldwide lab impact.[1]
DNK has raised $20.0M across 2 funding rounds. Most recently, it raised $16.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $16.0M Series A | Andreessen Horowitz, Dream Machine, Electric Ant, Flybridge Capital Partners, Greylock, Balaji Srinivasan | |
| Dec 1, 2020 | $4.0M Seed | Andreessen Horowitz, Dream Machine, Electric Ant, Flybridge Capital Partners, Greylock, Balaji Srinivasan, 75 & Sunny, David Vélez, Hadi Partovi, Kaszek Ventures, Latitud, NFX, Renegade Partners, Simon Borrero |